Actively Recruiting
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Led by University of California, San Francisco · Updated on 2026-05-01
66
Participants Needed
1
Research Sites
367 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This clinical trial tests the effect of induction chemotherapy response-guided radiation (de-escalated intensity-modulated radiation therapy \[IMRT\]) compared to standard IMRT in patients with Epstein-Barr virus (EBV)-associated nasopharyngeal cancer. Intensity-modulated radiation therapy (IMRT) is an advanced form of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Radiation therapy sometimes causes unwanted symptoms or side effects, including late effects such as hearing loss and dental problems. The severity of the side effects is related to the radiation dose received and the amount of tissue that received radiation. De-escalation IMRT uses lower doses of radiation based on a good response to induction chemotherapy. Giving de-escalated IMRT may be as effective as standard doses of IMRT in treating patients with EBV-associated nasopharyngeal cancer.
CONDITIONS
Official Title
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed nasopharyngeal carcinoma
- Epstein Barr virus (EBV)-associated nasopharyngeal carcinoma with detectable plasma EBV DNA
- Stage III-IVA disease with no distant metastasis confirmed by imaging and clinical evaluation
- Started or planning to start platinum-based induction systemic therapy
- Planning to receive intensity modulated radiation therapy (IMRT) with concurrent platinum-based systemic therapy
- Adjuvant immunotherapy after chemoradiation is allowed
- Age 18 years or older
- ECOG performance status 0 to 2 (Karnofsky 50% or higher)
- HIV-infected individuals on effective anti-retroviral therapy eligible
- Chronic hepatitis B patients on suppressive therapy if indicated
- Hepatitis C patients currently treated or cured
- Prior or concurrent malignancy allowed if not interfering with study safety or efficacy
- Agree to use contraception during study and for 60 days after radiation
- Ability to understand and sign informed consent
You will not qualify if you...
- Prior systemic chemotherapy for nasopharyngeal carcinoma other than induction chemotherapy
- Prior radiotherapy to nasopharynx or surrounding areas overlapping study fields
- Participation in another investigational drug or device study within 4 weeks before treatment
- Severe active comorbidities including major medical or psychiatric illness interfering with therapy
- Recent hospitalization for unstable angina, congestive heart failure, or peripheral vascular disease within 12 months
- Recent COPD exacerbation or respiratory illness requiring hospitalization within 30 days
- Active untreated infection requiring intravenous antibiotics at registration
- Child-bearing potential individuals without documented negative pregnancy test
- Female participants not meeting criteria for non-childbearing potential
- Any condition or social circumstance impairing ability to comply or interfering with safety or study endpoints
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
J
Jamese Johnson
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here